Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Elena Farè"'
Autor:
Melissa Bersanelli, Sebastiano Buti, Alessio Cortellini, Marco Bandini, Giuseppe Luigi Banna, Filippo Pederzoli, Elena Farè, Daniele Raggi, Patrizia Giannatempo, Ugo De Giorgi, Umberto Basso, Tania Losanno, Daniele Santini, Claudia Mucciarini, Marcello Tucci, Rosa Tambaro, Azzurra Farnesi, Orazio Caffo, Antonello Veccia, Emanuele Naglieri, Alberto Briganti, Giuseppe Procopio, Sandro Pignata, Andrea Necchi
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challeng
Externí odkaz:
https://doaj.org/article/5987142a35614d8f8862429246a6e6f1
Autor:
Marco Stellato, Elena Farè, Sebastiano Buti, Emanuele Naglieri, Marco Maruzzo, Melissa Bersanelli, Francesca Vignani, Sandro Pignata, Giuseppe Luigi Banna, Tania Losanno, Giuseppe Procopio, Ugo De Giorgi, Andrea Necchi, Umberto Basso, Patrizia Giannatempo, Rosa Tambaro, Daniele Raggi, Giulia Mazzaschi
Publikováno v:
Immunotherapy. 14:107-114
Background: Few data are available regarding the effectiveness of immune checkpoint inhibitors in advanced upper tract urothelial carcinoma (UTUC) patients. Methods: To provide a real-world experience with anti-PD-1/PD-L1-based therapy in UTUC patien
Autor:
Jeffrey S. Ross, Filippo Pederzoli, Andrea Salonia, Ewan A. Gibb, Ryan Dittamore, Maurizio Colecchia, Joep J. de Jong, Giorgio Gandaglia, Nicola Fossati, Marco Bandini, Patrizia Giannatempo, Roberta Lucianò, Laura Marandino, Andrea Gallina, Daniele Raggi, Yang Liu, Alberto Briganti, Elai Davicioni, Andrea Necchi, Francesco Montorsi, Elena Farè
Publikováno v:
European urology oncology, 4(6), 1001-1005. Elsevier
In the PURE-01 study, patients with muscle-invasive bladder cancer (MIBC) who achieved a pathological complete response (CR; ypT0N0) had tumor features suggesting that pre-existing immunity may promote response. We focused on fibroblast growth factor
Autor:
Marco Bianchi, Alberto Briganti, Filippo Pederzoli, Maurizio Colecchia, Marco Bandini, Barbara Padovano, Andrea Necchi, Francesco Montorsi, Andrea Gallina, Umberto Capitanio, Laura Marandino, Gianluca Serafini, Giorgio Gandaglia, Antonella Capozza, Daniele Raggi, Alessandra Alessi, Nicola Fossati, Patrizia Giannatempo, Andrea Salonia, Elena Farè
Publikováno v:
European Urology Focus. 7:1092-1099
Data regarding the incidence and prognostic impact of immune-related imaging changes, assessed by 18[F] fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scan, in patients receiving immune-checkpoint inhibitors (ICIs)
Autor:
Giorgio Gandaglia, Marco Bianchi, Jeffrey S. Ross, Siraj M. Ali, Alberto Briganti, Filippo Pederzoli, Nicola Fossati, Patrizia Giannatempo, Marco Bandini, Umberto Capitanio, Maurizio Colecchia, Federico Dehò, Daniele Raggi, Andrea Salonia, Renzo Colombo, Elena Farè, Andrea Gallina, Jon Chung, Laura Marandino, Russell Madison, Roberta Lucianò, Andrea Necchi, Francesco Montorsi
Publikováno v:
JNCI: Journal of the National Cancer Institute. 113:48-53
BackgroundIn the PURE-01 study (NCT02736266), we aimed to evaluate the ability to predict the pathologic complete response (pT0N0) after pembrolizumab by using clinical and tumor biomarkers.MethodsIn an open-label, single-arm, phase 2 study, 3 course
Autor:
Renzo Colombo, Jeffrey S. Ross, Giuseppina Calareso, Filippo Pederzoli, Elena Farè, Daniele Raggi, Marco Bandini, Umberto Capitanio, Marco Bianchi, Alberto Briganti, Antonella Messina, Siraj M. Ali, Maurizio Colecchia, Nicola Fossati, Patrizia Giannatempo, Andrea Gallina, Laura Marandino, Jon Chung, Russell Madison, Giorgio Gandaglia, Francesco De Cobelli, Roberta Lucianò, Andrea Necchi, Francesco Montorsi, Andrea Salonia, Federico Dehò
Publikováno v:
European Urology. 77:636-643
Background: In the PURE-01 study, pembrolizumab was given preoperatively before radical cystectomy in clinical T2-4aN0M0 patients. An accurate clinical response assessment may be useful for developing new perioperative strategies in these patients. O
Autor:
Jeffrey S. Ross, Filippo Pederzoli, Andrea Necchi, Maurizio Colecchia, Francesco Montorsi, Rodolfo Montironi, Andrea Salonia, Marco Bianchi, Renzo Colombo, Nicola Fossati, Giorgio Gandaglia, Alberto Briganti, Daniele Raggi, Umberto Capitanio, Patrizia Giannatempo, Federico Dehò, Roberta Lucianò, Andrea Gallina, Jon Chung, Laura Marandino, Russell Madison, Elena Farè, Siraj M. Ali, Marco Bandini
Publikováno v:
European Urology. 77:439-446
Background Patients with predominant variant histology (VH) of bladder tumors, defined as involving >50 % of the tumor specimens, are typically excluded from clinical trials, and for these patients, the efficacy of standard chemotherapy is limited. O
Autor:
Marco Bianchi, Alberto Briganti, Ewan A. Gibb, Joep J. de Jong, Maurizio Colecchia, Ryan Dittamore, Elena Farè, Andrea Gallina, Andrea Salonia, Joost L. Boormans, Andrea Necchi, Jeffrey S. Ross, Francesco Montorsi, Peter C. Black, Filippo Pederzoli, Yang Liu, Renzo Colombo, Laura Marandino, Umberto Capitanio, Nicola Fossati, Roberta Lucianò, Patrizia Giannatempo, Elai Davicioni, Giorgio Gandaglia, Marco Bandini, Daniele Raggi
Publikováno v:
European Urology, 77(6), 701-710. Elsevier
Background: The PURE-01 study (NCT02736266) evaluated the use of pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective: To evaluate the ability of molecular signatures to predict the pathological complete re
Autor:
Alberto Briganti, Melissa Bersanelli, Daniele Raggi, Sandro Pignata, Filippo Pederzoli, Antonello Veccia, Sebastiano Buti, Alessio Cortellini, Ugo De Giorgi, Emanuele Naglieri, Claudia Mucciarini, Daniele Santini, Marco Bandini, Giuseppe Procopio, Orazio Caffo, Giuseppe Luigi Banna, Andrea Necchi, A. Farnesi, Patrizia Giannatempo, R. Tambaro, Marcello Tucci, Elena Farè, Tania Losanno, Umberto Basso
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights. Oncology
Background: Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challeng
Autor:
Luigi Celio, Claudia Maggi, Giulia Bianchi, Monica Milano, Maria Silvia Cona, Claudio Vernieri, Gabriella Mariani, Marta Brambilla, Alessia Mennitto, Chiara Fabbroni, Elena Farè, Michele Prisciandaro, Filippo de Braud, Sara Cresta, Giuseppe Capri
Publikováno v:
Clinical Breast Cancer. 19:e306-e318
Single-agent gemcitabine is a moderately effective compound in metastatic breast cancer (mBC) treatment. Carboplatin is frequently used in addition to gemcitabine to improve tumor responses, but with an unclear effect on survival outcomes. In this st